Individualization of the subcutaneous amifostine dose during hypofractionated / accelerated radiotherapy.

Background: Individualization of the daily dose of amifostine may prove of value in achieving maximum cytoprotection during radiotherapy.

Patients And Methods: Using an algorithm based on: i) the gradual increase of the amifostine dose, ii) an amifostine tolerance-recording scale and iii) the intermittent administration of dexamethasone, the individualization of the subcutaneous amifostine dose was prospectively attempted in a large cohort of 132 cancer patients, treated with 12-15 consecutive fractions of 3.4-3.